feed,title,long_url,short_url
Benzinga,Eli Lilly Says Lebrikizumab Monthly Maintenance Dosing At Two Years Demonstrated Efficacy For Patients With Eczema,https://benzinga.com/markets/equities/23/10/35349114/eli-lilly-says-lebrikizumab-monthly-maintenance-dosing-at-two-years-demonstrated-efficacy-for-pa,https://da.gd/1A6n2e
